D
Dominik Paul Modest
Researcher at Charité
Publications - 203
Citations - 5780
Dominik Paul Modest is an academic researcher from Charité. The author has contributed to research in topics: Colorectal cancer & Cetuximab. The author has an hindex of 33, co-authored 146 publications receiving 4459 citations. Previous affiliations of Dominik Paul Modest include Ludwig Maximilian University of Munich & Humboldt University of Berlin.
Papers
More filters
Journal ArticleDOI
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann,Ludwig Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Ursula Vehling-Kaiser,Salah-Eddin Al-Batran,Tobias Heintges,Christian A. Lerchenmuller,Christoph Kahl,G. Seipelt,Frank Kullmann,Martina Stauch,Werner Scheithauer,Jörg Hielscher,Michael Scholz,Sebastian Müller,Hartmut Link,Norbert Niederle,Andreas Rost,Heinz-Gert Höffkes,Markus Moehler,Reinhard Udo Lindig,Dominik Paul Modest,Lisa Rossius,Thomas Kirchner,Andreas Jung,Sebastian Stintzing +26 more
TL;DR: The association with longer overall survival suggests that FOLFIRI plus cetuximab could be the preferred first-line regimen for patients with KRAS exon 2 wild-type metastatic colorectal cancer.
Journal ArticleDOI
The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials
TL;DR: A meta-analysis of first-line clinical trials available up to October 2016 demonstrates that PTL is prognostic in patients with metastatic colorectal cancer (mCRC) and supports the conclusion that patients with left-sided RAS wild-type mCRC should be preferentially treated with an anti-EGFR antibody.
Journal ArticleDOI
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Sebastian Stintzing,Sebastian Stintzing,Dominik Paul Modest,Dominik Paul Modest,Lisa Rossius,Markus M. Lerch,Ludwig Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Ursula Vehling-Kaiser,Salah-Eddin Al-Batran,Tobias Heintges,Christian A. Lerchenmuller,Christoph Kahl,G. Seipelt,Frank Kullmann,Martina Stauch,Werner Scheithauer,Swantje Held,Clemens Giessen-Jung,Markus Moehler,Andreas Jagenburg,Thomas Kirchner,Thomas Kirchner,Andreas Jung,Andreas Jung,Volker Heinemann,Volker Heinemann +27 more
TL;DR: The FIRE-3 trial as discussed by the authors compared first-line 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab with FOLFIRi plus bevacizumab in patients with KRAS exon 2 wild-type metastatic colorectal cancer.
Journal ArticleDOI
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
Dominik Paul Modest,Dominik Paul Modest,Ingrid Ricard,Volker Heinemann,Volker Heinemann,S. Hegewisch-Becker,W. Schmiegel,Rainer Porschen,Sebastian Stintzing,Sebastian Stintzing,U. Graeven,Dirk Arnold,L.F. von Weikersthal,Clemens Giessen-Jung,Arndt Stahler,H.-J. Schmoll,Andreas Jung,Andreas Jung,Thomas Kirchner,Thomas Kirchner,Andrea Tannapfel,Anke Reinacher-Schick +21 more
TL;DR: In this pooled analysis of metastatic colorectal cancer patients, mutations in KRAS, and BRAF were associated with inferior progression-free and overall survival compared with patients with non-mutated tumors.
Journal ArticleDOI
Treatment sequencing in metastatic colorectal cancer
TL;DR: Current treatment approaches and optimal treatment sequencing across the first-, second- and third-line settings in mCRC are reviewed, including biological aspects affecting sequencing and rechallenge.